Skip to main content
Quest Diagnostics10-Q: Major contract win

Fresenius Medical Care and Corewell Health partnerships drive 9.5% DIS volume increase

Source: Autobound Signal API · 71 signals tracked for Quest Diagnostics · updated

Get Quest Diagnostics' live signals in Claude or ChatGPT, or by API

AskWhat changed at Quest Diagnostics this week? Use Autobound signals for questdiagnostics.com.

What happened

Relationships with Corewell Health and increased laboratory testing at dialysis clinics owned by Fresenius Medical Care in the United States contributed 9.5% of DIS volume growth. Suppliers of clinical testing assays, dialysis diagnostics, and logistics services may see increased volume requirements.

Source

SEC EDGAROct 23, 2026

Quarterly report (Form 10-Q)

Quest Diagnostics 10-Q for Quarter ended Sep 30, 2026

Filing excerpt

DIS volume increased by 14.5% compared to the prior year period (principally driven by organic growth of 14.4%) of which 9.5% was due to both our new relationships with Corewell Health to provide Collaborative Lab Solutions and increasing our laboratory testing at dialysis clinics owned by Fresenius Medical Care in the United States.

sec.gov/Archives/edgar/data/1022079/000102207926000108/dgx-20260930.htmRead the full source

Other signals in this filing (4)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Major contract win

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Sep 30, 2026
Fiscal year end
09/30
Filed
Oct 23, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Percent
9.5% (volume increase attributable to Corewell Health and Fresenius Medical Care testing)

Details

CIK
1022079
Accession number
0001022079-26-000108
Timeframe
Current quarter
Quarter
Q3
Filing year
2026
Period end date
Sep 30, 2026
Why it matters
Scaling needs
Signal category
Revenue

Topics and mentions

Regions named

  • United States

Extraction

Confidence
High
Relevance
80%
Sentiment
Positive
Detected
Oct 27, 2026
signal_type
sec-10q
signal_subtype
majorContractWin

Use this data

Get every 10-Q signal for Quest Diagnostics and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Quest Diagnostics this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/c8dc52dc-14d7-480b-ac21-4b2fa6c58b54 returns this record as JSON. POST /v1/companies/enrich returns every signal for questdiagnostics.com.

{
  "signal_id": "c8dc52dc-14d7-480b-ac21-4b2fa6c58b54",
  "signal_type": "sec-10q",
  "signal_subtype": "majorContractWin",
  "detected_at": "2026-10-27T08:04:02.008+00:00",
  "company": {
    "name": "Quest Diagnostics",
    "domain": "questdiagnostics.com"
  },
  "data": {
    "detail": "Relationships with Corewell Health and increased laboratory testing at dialysis clinics owned by Fresenius Medical Care in the United States contributed 9.5% of DIS volume growth. Suppliers of clinical testing assays, dialysis diagnostics, and logistics services may see increased volume requirements.",
    "metrics": {
      "pct": 0.095,
      "timeframe": "current_quarter",
      "pct_context": "volume increase attributable to Corewell Health and Fresenius Medical Care testing"
    },
    "quarter": "Q3",
    "summary": "Fresenius Medical Care and Corewell Health partnerships drive 9.5% DIS volume increase",
    "excerpts": "DIS volume increased by 14.5% compared to the prior year period (principally driven by organic growth of 14.4%) of which 9.5% was due to both our new relationships with Corewell Health to provide Collaborative Lab Solutions and increasing our laboratory testing at dialysis clinics owned by Fresenius Medical Care in the United States.",
    "relevance": 0.8,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1022079/000102207926000108/dgx-20260930.htm",
    "filing_date": "2026-10-23",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "09/30",
    "period_end_date": "2026-09-30",
    "sales_relevance": "Scaling needs",
    "signal_category": "revenue",
    "regions_mentioned": [
      "United States"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.